Article
Biochemistry & Molecular Biology
Oliver Neuhaus, Wolfgang Koehler, Florian Then Bergh, Wolfgang Kristoferitsch, Juergen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Summary: This study aimed to investigate the correlation between clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. After 12 months of treatment, 13 patients showed improvement in all three fatigue assessment scales, while 5 patients deteriorated and 7 patients showed inconsistent effects. Fatigue and overall quality of life improved, but no clear correlation between clinical and molecular effects of GA was found in RRMS patients with fatigue.
Article
Medicine, Research & Experimental
Paulina Maria Reyes-Mata, Argelia Esperanza Rojas-Mayorquin, Lucrecia Carrera-Quintanar, Celia Gonzalez-Castillo, Mario Alberto Mireles-Ramirez, Jose de Jesus Guerrero-Garcia, Daniel Ortuno-Sahagun
Summary: This study aimed to investigate the serum levels of Pleiotrophin (PTN) in patients with Multiple Sclerosis (MS). The results showed that PTN serum levels were significantly higher in RRMS patients compared to the healthy control group, and were associated with sex, body mass index (BMI), and IFN-beta treatment.
ARCHIVES OF MEDICAL RESEARCH
(2022)
Review
Clinical Neurology
Massimiliano Mirabella, Pietro Annovazzi, Wallace Brownlee, Jeffrey A. Cohen, Christoph Kleinschnitz, Christian Wolf
Summary: Earlier diagnosis, access to disease-modifying therapies, and improved supportive care have positively influenced the disease course of multiple sclerosis, leading to improved long-term outcomes for patients. However, the complexity of treatment selection has increased due to the presence of comorbidities, immune senescence, and the growing number of approved therapies.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Pavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley L. Cohan, Ray Su, Robin Avila, Irene Koulinska, Jason P. Mendoza
Summary: This study found that dimethyl fumarate may be an effective treatment option for relapsing multiple sclerosis patients who experience suboptimal response to glatiramer acetate. In both first switch and early MS switch patients, most patients showed significant improvement in relapse rates and symptoms after 12 months of DMF treatment.
NEUROLOGY AND THERAPY
(2021)
Article
Chemistry, Multidisciplinary
Dina Erzina, Alice Capecchi, Sacha Javor, Jean-Louis Reymond
Summary: Researchers synthesized a library of peptide dendrimers with an amino acid composition similar to GA, some of which were as active as GA. Detailed profiling showed that the best hit dendrimer can induce the differentiation of monocytes towards an M2 state with a distinct immune marker profile. This peptide dendrimer might serve as a starting point to develop a well-defined immunomodulatory analog of GA.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Article
Clinical Neurology
Mahmoud A. AbdelRazek, Subhash Tummala, Fariha Khalid, Shahamat Tauhid, Youmna Jalkh, Samar Khalil, Shelley Hurwitz, Jonathan Zurawski, Rohit Bakshi
Summary: This study compared gray matter atrophy in patients with multiple sclerosis (MS) treated with glatiramer acetate (GA) and patients with clinically benign MS (BMS). The results showed that there was no significant change in gray matter and whole brain atrophy in the GA group over 2 years, similar to the BMS group.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Ignacio Casanova, Maria I. Dominguez-Mozo, Laura De Torres, Yolanda Aladro-Benito, Angel Garcia-Martinez, Patricia Gomez, Sara Abellan, Esther De Antonio, Roberto Alvarez-Lafuente
Summary: This study investigates the association between a preselected list of miRNAs in the serum of relapsing-remitting multiple sclerosis (RRMS) patients with therapeutic response to Glatiramer Acetate (GA) and clinical evolution. The findings suggest that certain miRNAs may serve as potential biomarkers for disease progression and response to treatment in multiple sclerosis.
Article
Immunology
Candace Marsters, Nabeela Nathoo, Lindsay Amatto, Russell Wong, Muhammad N. Mahmood, Jennifer A. McCombe
Summary: Glatiramer acetate, an old and safe therapy for relapsing-remitting multiple sclerosis, can rarely cause urticarial vasculitis. We present a case of normocomplementemic urticarial vasculitis diagnosed by skin punch biopsy in a patient treated with glatiramer acetate for five years. The urticaria resolved after treatment with steroids and an antihistamine, as well as discontinuing glatiramer acetate.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Niloufar Rahiman, Parvin Zamani, Leila Arabi, Seyedeh Hoda Alavizadeh, Aminreza Nikpoor, Mohammad Mashreghi, Ali Badiee, Mahmoud Reza Jaafari
Summary: The study explores the use of liposomal formulations of Glatiramer acetate (GA) to overcome the frequent administration rate required for MS therapy. The results show that liposomal GA has higher efficacy in a murine model of MS, suggesting its potential as a reliable nanomedicine-based platform for MS treatment.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Review
Clinical Neurology
Maddalena Sparaco, Luigi Carbone, Doriana Landi, Ylenia Ingrasciotta, Raffaella Di Girolamo, Giacomo Vitturi, Girolama Alessandra Marfia, Carlo Alviggi, Simona Bonavita
Summary: Multiple sclerosis (MS) predominantly affects women of fertile age and can impact fertility in various ways. The use of assisted reproductive technology (ART) in women with MS is increasing, but it is associated with a higher risk of disease relapse. Therefore, careful management is needed to minimize the risk and ensure a safe pregnancy in women with stable disease. Clinical and radiological monitoring should be performed during and after ART.
Article
Pharmacology & Pharmacy
Berke Karaahmet, John A. Olschowka, M. Kerry O'Banion
Summary: Alzheimer's disease (AD) is a neurodegenerative disorder with strong inflammatory components. However, using glatiramer acetate (GA) to reduce amyloid beta (Aβ) plaque pathology in a mouse model of AD showed only modest decreases in Aβ levels during the development of pathology and unexpectedly increased Aβ levels in later stages. The impact was significant only in female mice and there were no changes in microglial uptake or immune markers on microglia. Caution is needed when repurposing GA for AD treatment.
Article
Multidisciplinary Sciences
Ioana S. Barac, Vitalie Vacaras, Mihaela Iancu, Dafin F. Muresanu, Lucia M. Procopciuc
Summary: This study aimed to test the association between interferon and long-chain synthesis gene polymorphisms with multiple sclerosis (MS) patients. The results showed a significant correlation between serum levels of IL-27 and IL-23 with gene polymorphisms in RRMS patients.
Review
Health Care Sciences & Services
Maria Jose Zarzuelo-Romero, Cristina Perez-Ramirez, Yasmin Cura, Maria Isabel Carrasco-Campos, Luciana Maria Marangoni-Iglecias, Maria Carmen Ramirez-Tortosa, Alberto Jimenez-Morales
Summary: The response to glatiramer acetate (GA) therapy in MS patients may be influenced by genetic polymorphisms in genes such as CD86, CTSS, and FAS. Identifying these polymorphisms could serve as a predictive marker for the response to GA treatment in the future, but further validation studies are needed.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Clinical Neurology
Masoumeh Cheshmavar, Omid Mirmosayyeb, Negin Badihian, Shervin Badihian, Vahid Shaygannejad
Summary: The study found that both rituximab (RTX) and glatiramer acetate (GA) did not significantly affect the Expanded Disability Status Scale (EDSS) in secondary progressive multiple sclerosis (SPMS) patients, but were equally effective in reducing relapses.
ACTA NEUROLOGICA SCANDINAVICA
(2021)
Article
Pharmacology & Pharmacy
Peter Lipsky, Patrick T. Vallano, Jeffrey Smith, Walter Owens, Daniel Snider, Viswanath Bandaru, Yunfu Sun, Ross Wallingford, Joseph Duncan, Joshua Lewis, Jason Southall, Azeem Ansari, Hong Li
Summary: The study demonstrates the equivalence of Mylan's glatiramer acetate (MGA) to the reference product Copaxone(R) (COP) in terms of physicochemical properties, structural signatures, and biological activity. The findings provide compelling evidence that the FDA-approved generic MGA can be substituted for COP in the treatment of patients with relapsing-remitting multiple sclerosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Claudio Solaro, Rachele Di Giovanni, Erica Grange, Giampaolo Brichetto, Margit Mueller, Andrea Tacchino, Rita Bertoni, Francesco Patti, Angelo Pappalardo, Luca Prosperini, Letizia Castelli, Rosalba Rosato, Davide Cattaneo, Davide Marengo
Summary: The study aims to evaluate the associations between Manual Ability Measure-36 (MAM-36) and objective measures, including the Nine Hole Peg Test (9-HPT), Box and Block Test (BBT), and Hand Grip Strength (HGS) in people with multiple sclerosis (PwMS). The study found small correlations between MAM-36 and these objective measures, with different correlations seen in different subgroups. Combining 9-HPT and HGS can enhance the assessment of upper limb function in daily activities.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Carlo Pozzilli, Maura Pugliatti, Patrick Vermersch, Nikolaos Grigoriadis, Mona Alkhawajah, Laura Airas, Celia Oreja-Guevara
Summary: This article examines the impact of diagnostic definitions of progressive multiple sclerosis (MS) on clinical research, clinical trial design, and treatment decisions. The results show that inconsistent results in clinical studies of treatments for progressive MS may be attributed to differences in patient characteristics and endpoint definitions. Younger patients with more active disease are likely to benefit the most from available treatments. Therefore, treatment decisions should be based on individual patient's disease progression pattern and parameters, rather than their clinical phenotype. Careful selection of eligibility criteria and study endpoints is necessary for future studies in patients with progressive MS.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Letter
Clinical Neurology
Emilio Portaccio, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Ibrahima Diouf, Charles B. Malpas, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Francesco Patti, Vahid Shaygannejad, Serkan Ozakbas, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Raed Alroughani, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Cavit Boz, Francois Grand'Maison, Sherif Hamdy, Patrizia Sola, Diana Ferraro, Pierre Grammond, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Bassem Yamout, Ayse Altintas, Oliver Gerlach, Vincent van Pesch, Yolanda Blanco, Davide Maimone, Jeannette Lechner-Scott, Roberto Bergamaschi, Rana Karabudak, Gerardo Iuliano, Chris McGuigan, Elisabetta Cartechini, Michael Barnett, Stella Hughes, Maria Jose Sa, Claudio Solaro, Ludwig Kappos, Cristina Ramo-Tello, Edgardo Cristiano, Suzanne Hodgkinson, Daniele Spitaleri, Aysun Soysal, Thor Petersen, Mark Slee, Ernest Butler, Franco Granella, Koen de Gans, Pamela McCombe, Radek Ampapa, Bart Van Wijmeersch, Anneke van der Walt, Helmut Butzkueven, Julie Prevost, L. G. F. Sinnige, Jose Luis Sanchez-Menoyo, Steve Vucic, Guy Laureys, Liesbeth Van Hijfte, Dheeraj Khurana, Richard Macdonell, Riadh Gouider, Tamara Castillo-Trivino, Orla Gray, Eduardo Aguera-Morales, Abdullah Al-Asmi, Cameron Shaw, Norma Deri, Talal Al-Harbi, Yara Fragoso, Tunde Csepany, Angel Perez Sempere, Irene Trevino-Frenk, Jan Schepel, Fraser Moore, Tomas Kalincik
Summary: This study evaluated the impact of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). The results showed that patients with relapsing MS who received DMT had a reduced relapse incidence, lower risk of disability worsening, and greater chance of disability improvement. The effectiveness of DMT was influenced by the severity of disability, prior relapse rate, and prior cerebral magnetic resonance imaging activity, but not by age.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
News Item
Clinical Neurology
Maria Pia Amato, Emilio Portaccio
Summary: The first randomized, placebo-controlled trial of dimethyl fumarate in radiologically isolated syndrome patients demonstrated its efficacy in reducing the risk of a first clinical demyelinating event. These findings provide a foundation for preventive medicine in multiple sclerosis and underscore the importance of precise risk prognostication.
NATURE REVIEWS NEUROLOGY
(2023)
Article
Clinical Neurology
Simona Toscano, Clara Grazia Chisari, Adriana Meli, Chiara Finocchiaro, Salvatore Lo Fermo, Mario Zappia, Francesco Patti
Summary: The study found that there have been changes in pregnancy planning and management for women with multiple sclerosis (MS) over the past 15 years. Nowadays, more women of childbearing age are being treated with high-efficacy disease-modifying drugs (DMD) during pregnancy, leading to a reduced relapse rate before and after delivery without increased obstetric complications.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Pietro Annovazzi, Paola Banfi, Roberto Bergamaschi, Raffaella Clerici, Marta Zaffira Conti, Antonio Cortese, Roberta Fantozzi, Diana Ferraro, Mariano Fischetti, Maura Frigo, Maurizia Gatto, Paolo Immovilli, Stefania Leoni, Simona Malucchi, Giorgia Maniscalco, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Carlo Serrati, Rocco Totaro, Gabriella Turano, Paola Valentino, Mauro Zaffaroni, Cristina Zuliani, Diego Centonze
Summary: This study aimed to evaluate the association between cognitive profile, attitude, and preferences of patients concerning treatment choice in multiple sclerosis. The results showed that more than 50% of patients chose a collaborative role in making treatment decisions, and these patients had higher cognitive abilities.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
R. Veldkamp, M. D'hooge, B. M. Sandroff, J. DeLuca, D. Kos, A. Salter, A. Feinstein, M. P. Amato, G. Brichetto, J. Chataway, R. Farrell, N. D. Chiaravalloti, U. Dalgas, M. Filippi, J. Freeman, R. W. Motl, C. Meza, M. Inglese, M. A. Rocca, G. Cutter, P. Feys
Summary: Performing cognitive-motor dual tasks can negatively affect walking performance and cognitive function in individuals with progressive multiple sclerosis and cognitive impairment. This study examined the dual task performance in different disability levels and found that it significantly affected walking performance, with similar effects across disability subgroups.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study aims to develop an evidence-based vaccination strategy for pwMS who are candidates for disease-modifying therapies. A multidisciplinary working group conducted a systematic literature search and formulated 53 recommendations based on the quality of evidence. The goal of this study is to homogenize immunization practices in pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Editorial Material
Clinical Neurology
Matilde Inglese, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Medicine, General & Internal
Cristiano Scandurra, Laura Rosa, Antonio Carotenuto, Marcello Moccia, Sebastiano Arena, Antonio Ianniello, Agostino Nozzolillo, Mariavittoria Turrini, Lidia Mislin Streito, Gianmarco Abbadessa, Elisabetta Ferraro, Manuela Mattioli, Alessandro Chiodi, Nelson Mauro Maldonato, Simona Bonavita, Marinella Clerico, Cinzia Cordioli, Lucia Moiola, Francesco Patti, Luigi Lavorgna, Massimo Filippi, Giovanna Borriello, Emanuele D'Amico, Carlo Pozzilli, Vincenzo Brescia Morra, Maria Petracca, Roberta Lanzillo
Summary: Despite being a common issue, sexual dysfunction in people with multiple sclerosis (pwMS) is underinvestigated. This study aimed to assess the potential determinants of sexual dysfunction in pwMS by considering its relationship with disease severity, illness perception, and depressive symptoms. The results showed that disease severity indirectly affects sexual dysfunction through illness perception and depressive symptoms. Illness perception plays a more crucial role in sexual dysfunction for pwMS with mild disability. Modulating the effect of illness perception might be a valid approach to mitigate sexual dysfunction symptoms in pwMS.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Simona Toscano, Vittorio Oteri, Clara Grazia Chisari, Chiara Finocchiaro, Salvatore Lo Fermo, Paola Valentino, Antonio Bertolotto, Mario Zappia, Francesco Patti
Summary: Cerebrospinal fluid levels of neurofilament light chains (NFL) can predict the risk of clinical and radiological relapses in patients with Multiple Sclerosis (MS).
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Review
Clinical Neurology
Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, Eleonora Cocco, Nicola De Stefano, Claudio Gasperini, Paolo Gallo, Carlo Pozzilli, Maria Trojano, Massimo Filippi
Summary: Multiple sclerosis (MS) is a chronic neurological disease characterized by inflammation, degeneration, and demyelination. Cladribine tablets have been approved as an effective treatment option for highly active relapsing-remitting MS. A group of neurologists has proposed management pathways for patients completing the approved 4-year regimen, based on response to treatment and monitoring of disease activity. Re-treatment decisions should be made based on clinical and radiological assessments, as well as patient eligibility and preference.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maida, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Birgit Keller, Xavier Montalban, Eva Kubala Havrdova
Summary: Cladribine tablet treatment significantly improved the health-related quality of life in people with highly active relapsing multiple sclerosis, with good safety and tolerability.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Clara Grazia Chisari, Joe Guadagno, Peyman Adjamian, Carlos Vila Silvan, Teresa Greco, Makarand Bagul, Francesco Patti
Summary: A significant proportion of patients with multiple sclerosis-associated spasticity experienced a meaningful reduction in spasticity severity after 12 weeks of treatment with nabiximols.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)